2-Aminoindane
2-Aminoindane (2-AI) is a conformationally constrained amphetamine analogue in which the side chain is locked into a rigid indane ring. It is a noradrenaline-dominant stimulant sold as a research chemical, with limited older pharmacological literature but essentially no modern human safety data.
01 Overview
2-AI is the parent of the aminoindane class, structurally an amphetamine whose alkyl chain is fused into a rigid bicyclic ring. This constraint biases its activity toward noradrenaline and dopamine release with comparatively little serotonergic action, giving a stimulant rather than entactogenic profile.
The aminoindanes were explored in mid-20th-century pharmacology, so a little animal data exists, but 2-AI itself has no meaningful clinical characterisation. It re-emerged as a research chemical valued for a clean stimulant effect; users report strong cardiovascular stimulation.
02 Mechanism
Releaser and reuptake inhibitor acting mainly at noradrenaline and dopamine transporters, with weak serotonergic activity due to the rigid indane structure.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light | 15–40 mg | Insufflated | Unstudied; noted as harsh and strongly cardiovascular. |
| Common | 20–60 mg | Oral | Anecdotal only; no validated dosing. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| StimulationClean, energetic stimulation with little empathogenic quality. | Anecdotal | ||
| Increased focusReported improved concentration. | Anecdotal | ||
| Appetite suppressionReduced hunger typical of the class. | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Cardiovascular strainMarked tachycardia and hypertension are commonly reported and appear pronounced for this compound. | Severe | Prominent | Anecdotal | |
| InsomniaSleep disruption after dosing. | Moderate | Common | Anecdotal | |
| Anxiety and overstimulationRestlessness and anxiety at higher doses. | Moderate | Common | Anecdotal |